Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

pared to current standard therapy. Our development program for nitazoxanide in combination with peginterferon addresses this need and promises to change paradigms for therapy of chronic Hepatitis C. The planned study of nitazoxanide in combination with Intercell's therapeutic vaccine further underscores our commitment to being a leader in the development of next-generation therapies."

Intercell's investigational therapeutic vaccine has been designed to restore an effective immune response against HCV, which ultimately is deemed necessary for sustained clearance of the virus. In a successful proof-of-concept trial involving around 50 treatment-naïve genotype-1 CHC patients, an optimized schedule of therapeutic vaccination achieved viral load reductions of more than 75% (0.6 log) in patients with high baseline RNA levels. Importantly, this reduction was sustained for at least six months following the end of treatment. As in previous trials with the vaccine from Intercell, vaccination was safe and well tolerated with minimal side effects.

Nitazoxanide, the first of a new class of broad-spectrum antiviral drugs called the thiazolides,(1,2,3) is an investigational new drug for CHC. It is a potent inhibitor of HCV in replicon studies,(2) and laboratory studies indicate that it does not induce viral mutations that confer drug resistance.(3,4) Nitazoxanide is synergistic with interferon and direct acting antivirals in replicon studies.(2,5) In a clinical trial of nitazoxanide monotherapy in patients with genotype 4 CHC, 17% (4 of 23) patients achieved sustained virologic response (undetectable serum HCV RNA 24 weeks after end of therapy), with all responders having low baseline serum HCV RNA levels (<400,000 IU/mL).(6) In other clinical trials, the addition of nitazoxanide to peginterferon or peginterferon plus ribavirin was associated with improvement in sustained virologic response rates without increasing the toxicities associated with peginterferon
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... LAWRENCE, Mass. , Aug. 1, 2014  NxStage Medical, ... innovative dialysis products, today announced that Jeffrey H. Burbank ... Financial Officer, will present at the 34 th Annual ... Boston, MA , on Wednesday, August 13 ... event will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
(Date:7/31/2014)... , July 31, 2014  According to data ... Services, the 2015 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... GeneXpert(R) System ... ... today announced the U.S. Food & Drug Administration (FDA) categorized,Cepheid,s ... Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed for ...
... Michael J. Fox,Foundation today announced the availability of ... toward transformative treatments and a cure for,Parkinson,s disease., ... researchers through the,Foundation,s Pipeline Programs, five separate initiatives ... drug development pipeline. This includes,early-stage discovery research, translational ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 2Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 3Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 4
(Date:8/1/2014)... This week marks a significant milestone ... week of paying commissions to its independent distributor sales ... January 2005 total $1,405,954,677.06. , MonaVie distributors can be ... pays commissions in 18 different currencies, including: AUD, EUR, ... PLN, USD, SGD, KRW, TWD, THB and GBP. ...
(Date:8/1/2014)... A leading dress supplier, Discount-Dress.com, explores a variety of ... any lady’s wardrobe fashionable and exciting. Recently, the company has ... To attract more people, it is now launching a special ... to 65% off. , “Summer is the season of short ... to our collection of ‘ 2014 summer short styles .’ ...
(Date:8/1/2014)... August 01, 2014 Transparency Market ... the addition of a comprehensive report on the ... System Market (Large Volume, Disposable, Syringe, Ambulatory and ... Trends And Forecast, 2013 – 2019’ is now ... http://www.transparencymarketresearch.com . , To begin with, the report ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... Africa has a well-earned reputation as one of the world,s ... intense medical care can greatly improve a person,s chances of ... wreaks life-threatening havoc within the body by attacking multiple organ ... back on the basics of "good meticulous intensive care," supporting ...
Breaking Medicine News(10 mins):Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:Discount-Dress.com’s Top Trend Report: 2014 Summer Short Bridesmaid Dresses Now for Sale 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 2Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 3
... that vitamin C was vital for good health and could ... ,Dr Margret Vissers, from Otago University's Free Radical Research ... vitamin C was a vital part of healthy living and ... had a cold. ,"I've found that vitamin C ...
... nerve cells in the brain and lead to depression, according to ... and Science in North Chicago. ,The team led by Daniel ... rats for 20 minutes. The older rats quickly cornered, pinned down ... ,The younger rats became fearful and acted depressed in the ...
... below seven is fast depleting, which has sent the Ministry of ... Company CSL had stopped the production of the Tet-tox vaccine in ... is just enough to last till the end of this month. ... drugs will have to be used by those who are in ...
... New research suggests that a child’s race may ... tobacco toxins associated with environmental tobacco smoke (ETS). ... asthma, who are exposed to ETS, have significantly ... counterparts. ,“African American children suffer from ...
... question of bloodshot eyes anymore. After sleepless nights, a person’s ... has been found//. ,Sleep deprivation lowers metabolic ... colleagues at Walter Reed Army Institute of Research, report in ... group of volunteers to two sleepless nights, they found that ...
... Patients can start using their mobile phones when the ban ... in the hospitals because it was believed// that its electromagnetic ... per the directive issued from the Department of Health, cell ... equipments. ,This announcement has brought in cheer ...
Cached Medicine News:Health News:Vitamin C Could Help in Curbing Cancer 2Health News:Race Affects Tobacco Absorption in Children 2
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: